4. Jones J, Mato A, Coutre S, et al. Evaluation of 230 patients with relapsed/refractory deletion
17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. British journal
of haematology. 2018;182(4):504-512.
5. Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib Regimens versus Chemoimmunotherapy
in Older Patients with Untreated CLL. The New England journal of medicine.
2018;379(26):2517-2528.
6. O'Brien S, Furman RR, Coutre S, et al. Single-agent ibrutinib in treatment-naive and
relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood.
2018;131(17):1910-1919.
7. Ahn IE, Underbayev C, Albitar A, et al. Clonal evolution leading to ibrutinib resistance in chronic
lymphocytic leukemia. Blood. 2017;129(11):1469-1479.
8. Kipps TJ, Fraser G, Coutre SE, et al. Long-Term Studies Assessing Outcomes of Ibrutinib Therapy
in Patients With Del(11q) Chronic Lymphocytic Leukemia. Clinical lymphoma, myeloma &
leukemia. 2019;19(11):715-722 e716.
9. International CLLIPIwg. An international prognostic index for patients with chronic lymphocytic
leukaemia (CLL-IPI): a meta-analysis of individual patient data. The Lancet Oncology.
2016;17(6):779-790.
10. Thompson PA, O'Brien SM, Xiao L, et al. beta2 -microglobulin normalization within 6 months
of ibrutinib-based treatment is associated with superior progression-free survival in patients
with chronic lymphocytic leukemia. Cancer. 2016;122(4):565-573.